Amplifon (OTCMKTS:AMFPF) & BG Medicine (OTCMKTS:BGMD) Head to Head Survey

BG Medicine (OTCMKTS:BGMD) and Amplifon (OTCMKTS:AMFPF) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, earnings, institutional ownership, risk and valuation.

Profitability

This table compares BG Medicine and Amplifon’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BG Medicine	N/A	N/A	N/A
Amplifon	4.74%	14.28%	3.89%

Valuation and Earnings

This table compares BG Medicine and Amplifon”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BG Medicine	N/A	N/A	N/A	N/A	N/A
Amplifon	$2.61 billion	1.43	$157.31 million	$0.56	29.45

Amplifon has higher revenue and earnings than BG Medicine.

Analyst Recommendations

This is a summary of current ratings and price targets for BG Medicine and Amplifon, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BG Medicine	0	0	0	0	0.00
Amplifon	0	0	2	0	3.00

Given BG Medicine’s higher probable upside, equities analysts plainly believe BG Medicine is more favorable than Amplifon.

Risk & Volatility

BG Medicine has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, Amplifon has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500.

Summary

Amplifon beats BG Medicine on 6 of the 8 factors compared between the two stocks.

About BG Medicine

BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.

About Amplifon

Amplifon S.p.A. engages in the distribution of hearing solutions and the fitting of customized products that help people rediscover various emotions of sound in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Ampli-easy, Ampli-connect, Ampli-energy, and Ampli-mini hearing devices. It also operates Ampli-care, a platform to deliver audiological care experience; and Amplifon App to manage the device functions in real-time directly from smartphone. Amplifon S.p.A. was founded in 1950 and is headquartered in Milan, Italy. Amplifon S.p.A.